• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    3/27/24 4:31:13 PM ET
    $ALZN
    $ATHA
    $AVTX
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALZN alert in real time by email

    Gainers

    • Avalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 215.8% to $15.0 during Wednesday's after-market session. The market value of their outstanding shares is at $12.0 million.
    • Fresh2 Group (NASDAQ:FRES) stock moved upwards by 5.26% to $0.6. The company's market cap stands at $14.2 million.
    • Biora Therapeutics (NASDAQ:BIOR) shares rose 5.12% to $1.23. The company's market cap stands at $33.4 million. As per the news, the Q4 earnings report came out yesterday.
    • Athira Pharma (NASDAQ:ATHA) stock rose 5.07% to $2.69. The market value of their outstanding shares is at $103.0 million.
    • Clearside Biomedical (NASDAQ:CLSD) stock rose 4.79% to $1.75. The company's market cap stands at $130.7 million.
    • TFF Pharmaceuticals (NASDAQ:TFFP) stock increased by 4.7% to $6.9. The market value of their outstanding shares is at $16.3 million.

    Losers

    • Strata Skin Sciences (NASDAQ:SSKN) stock fell 12.5% to $0.39 during Wednesday's after-market session. The market value of their outstanding shares is at $13.6 million. As per the press release, Q4 earnings came out today.
    • Yield10 Bioscience (NASDAQ:YTEN) stock declined by 9.36% to $0.34. The company's market cap stands at $4.0 million.
    • Modular Medical (NASDAQ:MODD) stock declined by 9.24% to $1.77. The company's market cap stands at $54.8 million.
    • GlycoMimetics (NASDAQ:GLYC) stock fell 8.81% to $2.9. The company's market cap stands at $186.7 million. As per the news, the Q4 earnings report came out today.
    • Titan Pharma (NASDAQ:TTNP) shares fell 5.15% to $7.0. The market value of their outstanding shares is at $5.2 million.
    • Alzamend Neuro (NASDAQ:ALZN) stock declined by 5.01% to $0.99. The company's market cap stands at $6.5 million. The company's, Q3 earnings came out 2 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALZN
    $ATHA
    $AVTX
    $BIOR

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Avalo Therapeutics Inc.
    $AVTX
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    Avalo Therapeutics Inc.
    $AVTX
    9/5/2025Buy
    TD Cowen
    Avalo Therapeutics Inc.
    $AVTX
    8/15/2025Overweight
    Cantor Fitzgerald
    Clearside Biomedical Inc.
    $CLSD
    7/18/2025$2.00Buy → Hold
    Stifel
    Clearside Biomedical Inc.
    $CLSD
    7/18/2025Buy → Neutral
    Chardan Capital Markets
    Clearside Biomedical Inc.
    $CLSD
    7/18/2025Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $ALZN
    $ATHA
    $AVTX
    $BIOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rubinstein Samuel sold $18,804 worth of shares (14,094 units at $1.33) and bought $7,028 worth of shares (5,000 units at $1.41), decreasing direct ownership by 51% to 8,766 units (SEC Form 4)

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    11/18/25 4:35:42 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Director Horne William B. bought $3,285 worth of shares (3,334 units at $0.99), increasing direct ownership by 13% to 30,000 units (SEC Form 4)

    4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

    3/27/25 7:30:10 AM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ault Milton C Iii bought $2,969 worth of shares (2,905 units at $1.02) (SEC Form 4)

    4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

    3/25/25 4:30:07 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $ATHA
    $AVTX
    $BIOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Avalo Therapeutics with a new price target

    Mizuho initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $39.00

    12/18/25 9:07:24 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on Avalo Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $25.00 from $15.00 previously

    9/17/25 11:38:46 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $ATHA
    $AVTX
    $BIOR
    SEC Filings

    View All

    SEC Form 144 filed by Avalo Therapeutics Inc.

    144 - Avalo Therapeutics, Inc. (0001534120) (Subject)

    4/1/26 4:48:44 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Avalo Therapeutics Inc.

    SCHEDULE 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    4/1/26 1:02:57 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Modular Medical Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - Modular Medical, Inc. (0001074871) (Filer)

    3/31/26 4:35:09 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    $ALZN
    $ATHA
    $AVTX
    $BIOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sullivan Christopher Ryan

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    4/3/26 3:14:43 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Doyle Mittie

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    4/3/26 3:13:22 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Jain Rita

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    4/1/26 4:05:21 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $ATHA
    $AVTX
    $BIOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ALZN
    $ATHA
    $AVTX
    $BIOR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

    Bioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithium levels vs. standard lithium carbonateSuperior Brain Penetration: AL001 showed numerically higher lithium concentrations in all measured brain regions, including whole brainFaster Brain Uptake: AL001 reached peak brain concentration in 6.7 hours vs. 8.4 hours for standard lithium carbonateATLANTA, March 26, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive disorder ("MDD") and post-trauma

    3/26/26 8:00:00 AM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates

    Topline data expected from Phase 2 LOTUS trial of abdakibart (AVTX-009) for the treatment of hidradenitis suppurativa in the second quarter of 2026Cash, cash equivalents and short-term investments of approximately $98 million as of December 31, 2025 expected to provide runway into 2028 WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and year-end financial results for 2025. "2025 was a year of disciplined execution focused on the LOTUS trial, and we are thrilled to be approac

    3/23/26 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

    Head-to-head studies of AL001 versus marketed lithium carbonate will compare lithium blood and brain/brain-structure pharmacokinetics in bipolar disorder type 1 patientsTopline data expected in third quarter of 2026Topline data from the clinically completed "lithium in brain" imaging study in healthy subjects expected by the end of March 2026ATLANTA, March 16, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced the initi

    3/16/26 8:00:00 AM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XIPERE issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug XIPERE (ORIG-1) with active ingredient TRIAMCINOLONE ACETONIDE has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:22:37 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SUSVIMO issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug SUSVIMO (ORIG-1) with active ingredient RANIBIZUMAB has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:07:19 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $ATHA
    $AVTX
    $BIOR
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

    WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. "We are delighted to welcome Taylor and Ashley to Avalo as we enter a transformational period for the Company, including advancing AVTX-009 through the LOTUS Phase 2 trial in hidradenitis suppurativa and preparing for a data readout mid next year," said Dr. Garry Nei

    10/1/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

    WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the appointment of Kevin R. Lind to its Board of Directors. Mr. Lind brings more than 20 years of leadership in capital markets, strategy, business development and company building, including most recently guiding Longboard Pharmaceuticals to a multi-billion-dollar exit. "Kevin joins Avalo at an exciting time, as we continue to advance AVTX-009 through the Phase 2 LOTUS trial in hidradenitis suppurativa (HS) with topline data expected mid next year," said

    9/22/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

    WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. "We are pleased to welcome Dr. Jain to Avalo's Board of Directors," said Michael Heffernan, Chairman of the Board. "Rita's extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biopharma companies will be invaluable as we continue to advance AVTX-009, a high affinity anti-IL-1β monoclonal antibody in a Phase 2 trial for hidradenitis suppurativa (HS) and take a thought

    6/18/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $ATHA
    $AVTX
    $BIOR
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Breaking: Stock Acquired at Athira Pharma Inc. on Jun 25

    Recently, on June 25, 2024, Director Romano Kelly A bought $100,051 worth of shares in Athira Pharma Inc. This transaction involved acquiring 42,400 units at $2.36 per share, resulting in a significant increase in direct ownership by 111% to 80,715 units. The purchase was disclosed in the SEC Form 4 filing. Insider buying is often considered a bullish signal as insiders may have insights into the company's future performance. It's essential to analyze this insider purchase in conjunction with previous insider transactions to identify any patterns or trends. Taking into account the information from the SEC filings, several other insiders at Athira Pharma Inc. have also been active in the sto

    6/26/24 3:07:15 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    What Does the Recent Purchase at GlycoMimetics Inc. on Jun 20 Indicate?

    Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di

    6/20/24 6:20:00 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $ATHA
    $AVTX
    $BIOR
    Financials

    Live finance-specific insights

    View All

    Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

    Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors and TCGX Supports Development of Lasofoxifene through Phase 3 Clinical Topline Data Readout and Regulatory Milestones Conference Call Today at 8:30 am Eastern Time BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, today announced that it has entered into an agreement to acquire the right

    12/18/25 7:02:46 AM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update

    HORSHAM, Penn., Nov. 05, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report third quarter 2025 financial results on Thursday, November 13, 2025 after the market close. STRATA management will subsequently host a conference call at 4:30 p.m. ET on Thursday, November 13, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, in

    11/5/25 8:00:00 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

    HORSHAM, Penn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended June 30, 2025, and provides a corporate update. Second Quarter Highlights Historic expansion of CPT codes for reimbursement for inflammatory and auto-immune skin diseases, effectively tripling the covered patient population in the USPotential acceleration of expanded reimbursement coverage through application for G-codes to gain access by 2026 cycleSubmission of econom

    8/13/25 4:05:00 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $ALZN
    $ATHA
    $AVTX
    $BIOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by GlycoMimetics Inc.

    SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)

    11/27/24 2:22:44 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Modular Medical Inc.

    SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)

    11/25/24 7:18:33 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by TFF Pharmaceuticals Inc.

    SC 13G/A - TFF Pharmaceuticals, Inc. (0001733413) (Subject)

    11/19/24 4:05:58 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care